PolyPid Stock (NASDAQ:PYPD)


ForecastOwnershipChartTranscripts

Previous Close

$4.01

52W Range

$2.30 - $4.07

50D Avg

$3.62

200D Avg

$3.27

Market Cap

$40.46M

Avg Vol (3M)

$80.67K

Beta

1.49

Div Yield

-

PYPD Company Profile


PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

57

IPO Date

Jun 26, 2020

Website

PYPD Performance


Latest Earnings Call Transcripts


Q3 25Nov 12, 25 | 8:30 AM
Q2 25Aug 13, 25 | 8:30 AM
Q1 25May 14, 25 | 8:30 AM

Peer Comparison


TickerCompany
ANVSAnnovis Bio, Inc.
CELUCelularity Inc.
VERUVeru Inc.
EVAXEvaxion Biotech A/S
BTAIBioXcel Therapeutics, Inc.
PDSBPDS Biotechnology Corporation
BCABBioAtla, Inc.
RVPHReviva Pharmaceuticals Holdings, Inc.